Title : p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.

Pub. Date : 2016 Jan

PMID : 26440706






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Study objectives were to: 1) define the lowest safe dose of arsenic trioxide that transiently blocks p53 activation in patients and 2) assess the potential of LDA to decrease hematological toxicity from chemotherapy. Arsenic Trioxide tumor protein p53 Homo sapiens